{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T03:24:05Z","timestamp":1767842645165,"version":"3.49.0"},"reference-count":60,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2013,5,19]],"date-time":"2013-05-19T00:00:00Z","timestamp":1368921600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/2.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Support Care Cancer"],"published-print":{"date-parts":[[2013,8]]},"DOI":"10.1007\/s00520-013-1826-3","type":"journal-article","created":{"date-parts":[[2013,5,18]],"date-time":"2013-05-18T08:47:29Z","timestamp":1368866849000},"page":"2341-2349","source":"Crossref","is-referenced-by-count":40,"title":["Management of adverse events in patients with hormone receptor-positive breast cancer treated with everolimus: observations from a phase III clinical trial"],"prefix":"10.1007","volume":"21","author":[{"given":"Mary E.","family":"Peterson","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2013,5,19]]},"reference":[{"key":"1826_CR1","first-page":"1","volume-title":"Cancer facts and figures 2012","author":"American Cancer Society","year":"2012","unstructured":"American Cancer Society (2012) Cancer facts and figures 2012. American Cancer Society, Atlanta, pp 1\u201366"},{"key":"1826_CR2","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1200\/JCO.1999.17.5.1474","volume":"17","author":"JM Harvey","year":"1999","unstructured":"Harvey JM, Clark GM, Osborne CK, Allred DC (1999) Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. J Clin Oncol 17:1474\u20131481","journal-title":"J Clin Oncol"},{"key":"1826_CR3","unstructured":"National Comprehensive Cancer Network, Inc (2012) NCCN Clinical Practice Guidelines in Oncology. Breast Cancer V1.2012"},{"key":"1826_CR4","unstructured":"National Cancer Institute (2012) SEER Statistic Fact Sheet: Breast Cancer 2012"},{"key":"1826_CR5","doi-asserted-by":"crossref","first-page":"2101","DOI":"10.1200\/JCO.2003.04.194","volume":"21","author":"H Mouridsen","year":"2003","unstructured":"Mouridsen H, Gershanovich M, Sun Y et al (2003) Phase III study of letrozole versus tamoxifen as first-line therapy of advanced breast cancer in postmenopausal women: analysis of survival and update of efficacy from the International Letrozole Breast Cancer Group. J Clin Oncol 21:2101\u20132109","journal-title":"J Clin Oncol"},{"key":"1826_CR6","doi-asserted-by":"crossref","first-page":"5538","DOI":"10.1200\/JCO.2009.23.3734","volume":"27","author":"S Johnston","year":"2009","unstructured":"Johnston S, Pippen J Jr, Pivot X et al (2009) Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer. J Clin Oncol 27:5538\u20135546","journal-title":"J Clin Oncol"},{"key":"1826_CR7","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.1158\/1078-0432.CCR-09-1823","volume":"16","author":"SR Johnston","year":"2010","unstructured":"Johnston SR (2010) New strategies in estrogen receptor-positive breast cancer. Clin Cancer Res 16:1979\u20131987","journal-title":"Clin Cancer Res"},{"key":"1826_CR8","doi-asserted-by":"crossref","first-page":"R48","DOI":"10.1186\/bcr1536","volume":"8","author":"H Yamashita","year":"2006","unstructured":"Yamashita H, Toyama T, Nishio M, Ando Y, Hamaguchi M, Zhang Z, Kobayashi S, Fujii Y, Iwase H (2006) p53 protein accumulation predicts resistance to endocrine therapy and decreased post-relapse survival in metastatic breast cancer. Breast Cancer Res 8:R48","journal-title":"Breast Cancer Res"},{"key":"1826_CR9","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1016\/j.breast.2006.01.007","volume":"15","author":"D Dodwell","year":"2006","unstructured":"Dodwell D, Wardley A, Johnston S (2006) Postmenopausal advanced breast cancer: options for therapy after tamoxifen and aromatase inhibitors. Breast 15:584\u2013594","journal-title":"Breast"},{"key":"1826_CR10","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1056\/NEJMoa066838","volume":"356","author":"G Hudes","year":"2007","unstructured":"Hudes G, Carducci M, Tomczak P et al (2007) Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 356:2271\u20132281","journal-title":"N Engl J Med"},{"key":"1826_CR11","doi-asserted-by":"crossref","first-page":"4256","DOI":"10.1002\/cncr.25219","volume":"116","author":"RJ Motzer","year":"2010","unstructured":"Motzer RJ, Escudier B, Oudard S et al (2010) Phase 3 trial of everolimus for metastatic renal cell carcinoma: final results and analysis of prognostic factors. Cancer 116:4256\u20134265","journal-title":"Cancer"},{"key":"1826_CR12","doi-asserted-by":"crossref","first-page":"5755","DOI":"10.1158\/1078-0432.CCR-06-0118","volume":"12","author":"M Hidalgo","year":"2006","unstructured":"Hidalgo M, Buckner JC, Erlichman C, Pollack MS, Boni JP, Dukart G, Marshall B, Speicher L, Moore L, Rowinsky EK (2006) A phase I and pharmacokinetic study of temsirolimus (CCI-779) administered intravenously daily for 5 days every 2 weeks to patients with advanced cancer. Clin Cancer Res 12:5755\u20135763","journal-title":"Clin Cancer Res"},{"key":"1826_CR13","doi-asserted-by":"crossref","first-page":"3822","DOI":"10.1200\/JCO.2008.20.7977","volume":"27","author":"G Hess","year":"2009","unstructured":"Hess G, Herbrecht R, Romaguera J et al (2009) Phase III study to evaluate temsirolimus compared with investigator\u2019s choice therapy for the treatment of relapsed or refractory mantle cell lymphoma. J Clin Oncol 27:3822\u20133829","journal-title":"J Clin Oncol"},{"key":"1826_CR14","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1056\/NEJMoa1009290","volume":"364","author":"JC Yao","year":"2011","unstructured":"Yao JC, Shah MH, Ito T et al (2011) Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med 364:514\u2013523","journal-title":"N Engl J Med"},{"key":"1826_CR15","doi-asserted-by":"crossref","first-page":"827","DOI":"10.2217\/fon.11.57","volume":"7","author":"JE Dancey","year":"2011","unstructured":"Dancey JE, Monzon J (2011) Ridaforolimus: a promising drug in the treatment of soft-tissue sarcoma and other malignancies. Future Oncol 7:827\u2013839","journal-title":"Future Oncol"},{"key":"1826_CR16","doi-asserted-by":"crossref","first-page":"5314","DOI":"10.1200\/JCO.2005.66.130","volume":"23","author":"S Chan","year":"2005","unstructured":"Chan S, Scheulen ME, Johnston S et al (2005) Phase II study of temsirolimus (CCI-779), a novel inhibitor of mTOR, in heavily pretreated patients with locally advanced or metastatic breast cancer. J Clin Oncol 23:5314\u20135322","journal-title":"J Clin Oncol"},{"key":"1826_CR17","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1056\/NEJMoa1109653","volume":"366","author":"J Baselga","year":"2012","unstructured":"Baselga J, Campone M, Piccart M et al (2012) Everolimus in postmenopausal hormone receptor-positive advanced breast cancer. N Engl J Med 366:520\u2013529","journal-title":"N Engl J Med"},{"key":"1826_CR18","doi-asserted-by":"crossref","unstructured":"Hortobagyi GN, Piccart M, Rugo H, et al. (2011) Everolimus for postmenopausal women with advanced breast cancer: Updated results of the BOLERO 2 Phase III trial. Presented at San Antonio Breast Cancer Symposium, San Antonio, December 8, 2011; S3\u2013S7","DOI":"10.1158\/0008-5472.SABCS11-S3-7"},{"key":"1826_CR19","doi-asserted-by":"crossref","first-page":"2630","DOI":"10.1200\/JCO.2008.18.8391","volume":"27","author":"J Baselga","year":"2009","unstructured":"Baselga J, Semiglazov V, van Dam P et al (2009) Phase II randomized study of neoadjuvant everolimus plus letrozole compared with placebo plus letrozole in patients with estrogen receptor-positive breast cancer. J Clin Oncol 27:2630\u20132637","journal-title":"J Clin Oncol"},{"key":"1826_CR20","doi-asserted-by":"crossref","first-page":"2278","DOI":"10.1200\/JCO.2008.20.0766","volume":"27","author":"F Meric-Bernstam","year":"2009","unstructured":"Meric-Bernstam F, Gonzalez-Angulo AM (2009) Targeting the mTOR signaling network for cancer therapy. J Clin Oncol 27:2278\u20132287","journal-title":"J Clin Oncol"},{"key":"1826_CR21","doi-asserted-by":"crossref","first-page":"214","DOI":"10.2174\/157488411797189433","volume":"6","author":"HD Husseinzadeh","year":"2011","unstructured":"Husseinzadeh HD, Garcia JA (2011) Therapeutic rationale for mTOR inhibition in advanced renal cell carcinoma. Curr Clin Pharmacol 6:214\u2013221","journal-title":"Curr Clin Pharmacol"},{"key":"1826_CR22","unstructured":"Novartis Pharmaceuticals Corporation (2012) Afinitor (everolimus) tablets for oral administration. Novartis Pharmaceuticals Corporation, East Hanover, NJ"},{"key":"1826_CR23","volume-title":"Zortress (tablets for oral administration)","author":"AG Novartis Pharma Stein","year":"2010","unstructured":"Novartis Pharma Stein AG (2010) Zortress (tablets for oral administration). Novartis Pharma Stein AG, Stein, Switzerland"},{"key":"1826_CR24","unstructured":"Novartis (2012) Certican. Zuellig Pharma, Malaysia"},{"key":"1826_CR25","unstructured":"Piccart M, Baselga J, Noguchi S, et al. (2012) Final progression-free survival analysis of BOLERO-2: a phase III trial of everolimus for postmenopausal women with advanced breast cancer. Presented at: 2012 CTRC\u2013AACR San Antonio Breast Cancer Symposium; San Antonio, December 4\u20138, 2012; P6-04-02"},{"key":"1826_CR26","first-page":"263","volume":"4","author":"C Wojtaszek","year":"2000","unstructured":"Wojtaszek C (2000) Management of chemotherapy-induced stomatitis. Clin J Oncol Nurs 4:263\u2013270","journal-title":"Clin J Oncol Nurs"},{"key":"1826_CR27","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1016\/j.ejca.2011.02.014","volume":"47","author":"C Porta","year":"2011","unstructured":"Porta C, Ostanto S, Ravaud A et al (2011) Management of adverse events associated with the use of everolimus in patients with advanced renal cell carcinoma. Eur J Cancer 47:1287\u20131298","journal-title":"Eur J Cancer"},{"key":"1826_CR28","doi-asserted-by":"crossref","first-page":"E83","DOI":"10.1188\/11.CJON.E83-E89","volume":"15","author":"AP Pilotte","year":"2011","unstructured":"Pilotte AP, Hohos MB, Polson KM, Huftalen TM, Treister N (2011) Managing stomatitis in patients treated with Mammalian target of rapamycin inhibitors. Clin J Oncol Nurs 15:E83\u2013E89","journal-title":"Clin J Oncol Nurs"},{"key":"1826_CR29","doi-asserted-by":"crossref","first-page":"290","DOI":"10.3322\/canjclin.51.5.290","volume":"51","author":"WJ Kostler","year":"2001","unstructured":"Kostler WJ, Hejna M, Wenzel C, Zielinski CC (2001) Oral mucositis complicating chemotherapy and\/or radiotherapy: options for prevention and treatment. CA Cancer J Clin 51:290\u2013315","journal-title":"CA Cancer J Clin"},{"key":"1826_CR30","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1188\/04.ONF.S4.13-23","volume":"31","author":"J Eilers","year":"2004","unstructured":"Eilers J (2004) Nursing interventions and supportive care for the prevention and treatment of oral mucositis associated with cancer treatment. Oncol Nurs Forum 31:13\u201323","journal-title":"Oncol Nurs Forum"},{"key":"1826_CR31","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1002\/cncr.24696","volume":"116","author":"S Sonis","year":"2010","unstructured":"Sonis S, Treister N, Chawla S, Demetri G, Haluska F (2010) Preliminary characterization of oral lesions associated with inhibitors of mammalian target of rapamycin in cancer patients. Cancer 116:210\u2013215","journal-title":"Cancer"},{"key":"1826_CR32","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1188\/08.CJON.141-152","volume":"12","author":"DJ Harris","year":"2008","unstructured":"Harris DJ, Eilers J, Harriman A, Cashavelly BJ, Maxwell C (2008) Putting evidence into practice: evidence-based interventions for the management of oral mucositis. Clin J Oncol Nurs 12:141\u2013152","journal-title":"Clin J Oncol Nurs"},{"key":"1826_CR33","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1080\/07315724.1997.10718644","volume":"16","author":"NW Flodin","year":"1997","unstructured":"Flodin NW (1997) The metabolic roles, pharmacology, and toxicology of lysine. J Am Coll Nutr 16:7\u201321","journal-title":"J Am Coll Nutr"},{"key":"1826_CR34","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1007\/s11523-009-0107-z","volume":"4","author":"K Sankhala","year":"2009","unstructured":"Sankhala K, Mita A, Kelly K, Mahalingam D, Giles F, Mita M (2009) The emerging safety profile of mTOR inhibitors, a novel class of anticancer agents. Target Oncol 4:135\u2013142","journal-title":"Target Oncol"},{"key":"1826_CR35","doi-asserted-by":"crossref","unstructured":"Balagula Y, Rosen A, Tan BH et al (2012) Clinical and histopathologic characteristics of rash in cancer patients treated with mammalian target of rapamycin inhibitors. Cancer 118:5078\u20135083","DOI":"10.1002\/cncr.27505"},{"key":"1826_CR36","first-page":"1","volume-title":"Tips for managing treatment-related rash and dry skin","author":"SB Fleishman","year":"2012","unstructured":"Fleishman SB, Fox LP, Garfield DH, Viele CS, Messner C (2012) Tips for managing treatment-related rash and dry skin. Cancer Care, New York, pp 1\u201320"},{"key":"1826_CR37","unstructured":"American Diabetes Association (2012) Hyperglycemia and Diabetes, Available at: URL: http:\/\/www.medicinenet.com\/hyperglycemia\/article.htm . Accessed February 7, 2012"},{"key":"1826_CR38","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1007\/s11523-011-0174-9","volume":"6","author":"SA Soefje","year":"2011","unstructured":"Soefje SA, Karnad A, Brenner AJ (2011) Common toxicities of mammalian target of rapamycin inhibitors. Target Oncol 6:125\u2013129","journal-title":"Target Oncol"},{"key":"1826_CR39","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1016\/j.ejca.2011.06.054","volume":"48","author":"V Grunwald","year":"2012","unstructured":"Grunwald V, Karakiewics PI, Bavbek SE et al (2012) An international expanded-access programme of everolimus: addressing safety and efficacy in patients with metastatic renal cell carcinoma who progress after initial vascular endothelial growth factor receptor\u2013tyrosine kinase inhibitor therapy. Eur J Cancer 48:324\u2013332","journal-title":"Eur J Cancer"},{"key":"1826_CR40","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1007\/s00125-007-0873-z","volume":"51","author":"DM Nathan","year":"2008","unstructured":"Nathan DM, Buse JB, Davidson MB, Ferrannini E, Holman RR, Sherwin R, Zinman B (2008) Management of hyperglycaemia in type 2 diabetes mellitus: a consensus algorithm for the initiation and adjustment of therapy: update regarding the thiazolidinediones. Diabetologia 51:8\u201311","journal-title":"Diabetologia"},{"key":"1826_CR41","doi-asserted-by":"crossref","unstructured":"Hollebecque A, Clamp A, Horsley L, Morgan JA, Bahleda R, George S, Shaw D, Lauchle JO, Ware J, Desai R, Wu J, Fu L, Jayson GC, Soria JC, Wagner AJ (2011) A phase I study evaluating the pharmacokinetics (PK) and pharmacodynamic (PD) activity of the dual PI3K\/mTOR inhibitor GDC-0980 administered once weekly (QW). Presented at: AACR\u2013NCI\u2013EORTC International Conference: Molecular Targets and Cancer Therapeutics, November 12\u201316, 2011, San Francisco, CA","DOI":"10.1158\/1535-7163.TARG-11-B153"},{"key":"1826_CR42","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1164\/rccm.200911-1720OC","volume":"182","author":"DA White","year":"2010","unstructured":"White DA, Camus P, Endo M et al (2010) Noninfectious pneumonitis after everolimus therapy for advanced renal cell carcinoma. Am J Respir Crit Care Med 182:396\u2013403","journal-title":"Am J Respir Crit Care Med"},{"key":"1826_CR43","doi-asserted-by":"crossref","first-page":"758s","DOI":"10.1158\/1078-0432.CCR-06-1986","volume":"13","author":"D Cho","year":"2007","unstructured":"Cho D, Signoretti S, Regan M, Mier JW, Atkins MB (2007) The role of mammalian target of rapamycin inhibitors in the treatment of advanced renal cancer. Clin Cancer Res 13:758s\u2013763s","journal-title":"Clin Cancer Res"},{"key":"1826_CR44","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1016\/j.ejca.2006.03.015","volume":"42","author":"I Duran","year":"2006","unstructured":"Duran I, Siu LL, Oza AM, Chung TB, Sturgeon J, Townsley CA, Pond GR, Seymour L, Niroumand M (2006) Characterisation of the lung toxicity of the cell cycle inhibitor temsirolimus. Eur J Cancer 42:1875\u20131880","journal-title":"Eur J Cancer"},{"key":"1826_CR45","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.jhep.2012.02.010","volume":"57","author":"European Association for the Study of the Liver","year":"2012","unstructured":"European Association for the Study of the Liver (2012) EASL Clinical Practice Guidelines: management of chronic hepatitis B virus infection. J Hepatol 57:167\u2013185","journal-title":"J Hepatol"},{"key":"1826_CR46","unstructured":"National Comprehensive Cancer Network, Inc. (2012). NCCN Clinical Practice Guidelines in Oncology. Cancer-Related Fatigue V1.2012)"},{"key":"1826_CR47","unstructured":"National Institutes of Health (2009) Common terminology criteria for adverse events (CTCAE) Version 4.0. US Department of Health and Human Services, National Institutes of Health, National Cancer Institute, NIH Publication No. 03-5410"},{"key":"1826_CR48","first-page":"1","volume-title":"Putting evidence into practice: improving oncology patients outcomes","author":"LH Eaton","year":"2009","unstructured":"Eaton LH, Tipton JM (2009) Fatigue. In: Eaton LH, Tipton JM (eds) Putting evidence into practice: improving oncology patients outcomes. Oncology Nursing Society, Pittsburgh, pp 1\u2013324"},{"key":"1826_CR49","doi-asserted-by":"crossref","first-page":"2918","DOI":"10.1200\/JCO.2004.04.132","volume":"22","author":"AB Benson III","year":"2004","unstructured":"Benson AB III, Ajani JA, Catalano RB et al (2004) Recommended guidelines for the treatment of cancer treatment-induced diarrhea. J Clin Oncol 22:2918\u20132926","journal-title":"J Clin Oncol"},{"key":"1826_CR50","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1177\/1758834009355164","volume":"2","author":"A Stein","year":"2010","unstructured":"Stein A, Voigt W, Jordan K (2010) Chemotherapy-induced diarrhea: pathophysiology, frequency, and guideline-based management. Ther Adv Med Oncol 2:51\u201363","journal-title":"Ther Adv Med Oncol"},{"key":"1826_CR51","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1016\/S0889-8588(02)00019-9","volume":"16","author":"DJ Dudgeon","year":"2002","unstructured":"Dudgeon DJ (2002) Managing dyspnea and cough. Hematol Oncol Clin North Am 16:557\u2013577","journal-title":"Hematol Oncol Clin North Am"},{"key":"1826_CR52","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1007\/s005200050255","volume":"7","author":"C Ripamonti","year":"1999","unstructured":"Ripamonti C (1999) Management of dyspnea in advanced cancer patients. Support Care Cancer 7:233\u2013243","journal-title":"Support Care Cancer"},{"key":"1826_CR53","first-page":"101","volume":"3","author":"P Glorieux","year":"2009","unstructured":"Glorieux P, Marion P (2009) Management of dyspnea in advanced cancer patients. BJMO 3:101\u2013105","journal-title":"BJMO"},{"key":"1826_CR54","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1038\/ncponc0451","volume":"3","author":"J Bohlius","year":"2006","unstructured":"Bohlius J, Weingart O, Trelle S, Engert A (2006) Cancer-related anemia and recombinant human erythropoietin\u2014an updated overview. Nat Clin Pract Oncol 3:152\u2013164","journal-title":"Nat Clin Pract Oncol"},{"key":"1826_CR55","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1634\/theoncologist.10-9-743","volume":"10","author":"P Barrett-Lee","year":"2005","unstructured":"Barrett-Lee P, Bokemeyer C, Gascon P, Nortier JW, Schneider M, Schrijvers D, Van Belle S (2005) Management of cancer-related anemia in patients with breast or gynecologic cancer: new insights based on results from the European Cancer Anemia Survey. Oncologist 10:743\u2013757","journal-title":"Oncologist"},{"key":"1826_CR56","unstructured":"National Comprehensive Cancer Network, Inc (2012) NCCN Clinical Practice Guidelines in Oncology. Cancer and Chemotherapy-Induced Anemia V1.2012, pp 1\u201340"},{"issue":"suppl 1","key":"1826_CR57","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1634\/theoncologist.2009-S1-43","volume":"14","author":"JL Spivak","year":"2009","unstructured":"Spivak JL, Gascon P, Ludwig H (2009) Anemia management in oncology and hematology. Oncologist 14(suppl 1):43\u201356","journal-title":"Oncologist"},{"key":"1826_CR58","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1634\/theoncologist.3-4-275","volume":"3","author":"DH Henry","year":"1998","unstructured":"Henry DH (1998) Supplemental iron: a key to optimizing the response of cancer-related anemia to rHuEPO? Oncologist 3:275\u2013278","journal-title":"Oncologist"},{"key":"1826_CR59","first-page":"1105","volume":"71","author":"PT Giboney","year":"2005","unstructured":"Giboney PT (2005) Mildly elevated liver transaminase levels in the asymptomatic patient. Am Fam Physician 71:1105\u20131110","journal-title":"Am Fam Physician"},{"key":"1826_CR60","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.1053\/gast.2002.36060","volume":"123","author":"American Gastroenterological Association","year":"2002","unstructured":"American Gastroenterological Association (2002) Medical position statement: evaluation of liver chemistry tests. Gastroenterology 123:1364\u20131366","journal-title":"Gastroenterology"}],"container-title":["Supportive Care in Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-013-1826-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00520-013-1826-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-013-1826-3","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,10]],"date-time":"2024-05-10T21:55:12Z","timestamp":1715378112000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00520-013-1826-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,5,19]]},"references-count":60,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2013,8]]}},"alternative-id":["1826"],"URL":"https:\/\/doi.org\/10.1007\/s00520-013-1826-3","relation":{},"ISSN":["0941-4355","1433-7339"],"issn-type":[{"value":"0941-4355","type":"print"},{"value":"1433-7339","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,5,19]]}}}